Combination therapy with caspofungin and amphotericin B lipid complex [4]

American Journal of Health-System Pharmacy

Volumn 59, Issue 1, 2002, Pages 80-81

  Lum, Linda R ^a   Turco, Thomas F ^a   Leone, John ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; COTRIMOXAZOLE; LEVOFLOXACIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ASPERGILLOSIS; BRADYCARDIA; CANDIDA ALBICANS; CASE REPORT; CORONARY ARTERY DISEASE; CRITICAL ILLNESS; HEART ARREST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; LETTER; LUNG ABSCESS; MALE; MYCOSIS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; STAPHYLOCOCCUS EPIDERMIDIS; STENOTROPHOMONAS MALTOPHILIA; VENTILATOR;

EID: 0036235574     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.1.80     Document Type: Letter

References (6)

1. Caspofungin acetate: An antifungal agent
2. Echinocandins and pneumocandins - A new antifungal class with a novel mode of action
3. In vitro preclinical evaluation studies with the echinocandin antifungal MK-09991 (L-743,872)
4. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
5. Caspofungin: An echinocandin antifungal for the treatment of invasive aspergillosis